

**Yook-Wah Choi,^{a,b} Sujit Dutta,^c
 Burtram C. Fielding^b and Yee-Joo
 Tan^{a,d,*}**

^aCancer and Developmental Cell Biology
 Division, Institute of Molecular and Cell
 Biology, A*STAR (Agency for Science,
 Technology and Research), 61 Biopolis Drive,
 Singapore 138673, Singapore, ^bMolecular
 Virology Laboratory, Department of Medical
 Biosciences, University of the Western Cape,
 Bellville 7535, South Africa, ^cSchool of
 Biological Sciences, Nanyang Technological
 University, Singapore 637551, Singapore, and
^dDepartment of Microbiology, Yong Loo Lin
 School of Medicine, National University of
 Singapore, Singapore 117597, Singapore

Correspondence e-mail:
 mcbtanyj@imcb.a-star.edu.sg,
 yee_joo_tan@nuhs.edu.sg

Received 1 October 2009
 Accepted 9 December 2009



© 2010 International Union of Crystallography
 All rights reserved

Expression, purification and preliminary crystallographic analysis of recombinant human DEAD-box polypeptide 5

The DEAD-box RNA helicase DDX5 is involved in many aspects of RNA processing and has been implicated in a number of cellular processes involving alteration of RNA secondary structure. The N-terminal region of DDX5, which contains the conserved domain 1 of the DEAD-box helicases, has been cloned and expressed in *Escherichia coli* and purified. Here, the crystallization and preliminary diffraction analysis of this region is reported. X-ray diffraction data were processed to a resolution of 2.7 Å. The crystals belonged to space group *I*222, with unit-cell parameters $a = 66.18$, $b = 73.80$, $c = 104.00$ Å, $\alpha = \beta = \gamma = 90^\circ$.

1. Introduction

RNA helicases are involved in all aspects of RNA metabolism. They are ATPases with RNA-binding and RNA-unwinding activities and are involved in transcription, pre-mRNA splicing, ribosome biogenesis, mRNA nuclear export, translation initiation and degradation of mRNA (Linder, 2006; Cordin *et al.*, 2006).

DDX5 (also known as p68) was first discovered owing to its cross-reactivity with a monoclonal antibody of the large T antigen of simian virus 40 (Lane & Hoeffler, 1980). Subsequent analysis of the DNA sequence of DDX5 revealed extensive homology to the translation initiation factor eIF-4A. The molecular similarity of DDX5 to both the large T antigen and eIF-4A, which are an ATP-dependent DNA helicase and an ATP-dependent RNA helicase, respectively, implied that DDX5 may function as an RNA or DNA helicase (Ford *et al.*, 1988). DDX5 belongs to the DEAD-box family of proteins, which are named after their conserved amino-acid sequence Asp-Glu-Ala-Asp (D-E-A-D; Linder *et al.*, 1989). Based on their conserved sequence motifs, they are classified into superfamily 2 (SF2) of the helicases (Gorbalenya & Koonin, 1993). The DEAD-box family of helicases is characterized by the unique Q motif as well as eight other conserved motifs (Tanner *et al.*, 2003). The motifs Q, I (Walker A, phosphate-binding P-loop), Ia, Ib, II (Walker B, DExD box) and III form domain 1, while motifs IV, V and VI form domain 2 (Cordin *et al.*, 2006; Tanner *et al.*, 2003). Over the past decade, an increasing number of DEAD-box RNA helicase structures have been determined (Hogbom *et al.*, 2007; Sengoku *et al.*, 2006; Shi *et al.*, 2004; Carmel & Matthews, 2004; Caruthers *et al.*, 2000; Benz *et al.*, 1999).

DDX5 has been implicated in a wide range of biological processes, with early studies reporting its possible involvement in the regulation of differentiation/maturation of various animal and human cells (Abdelhaleem, 2005). Subsequently, it was shown to bind, unwind and rearrange RNA secondary structures (Rossler *et al.*, 2001) and was also shown to be crucial in the processing, alternate splicing and degradation of mRNA (Fuller-Pace, 2006; Abdelhaleem, 2005). DDX5 also acts as a transcriptional co-regulator of hormone receptors and transcription factors of differentiation and transcriptional initiation and mRNA decay (Fuller-Pace & Ali, 2008; Abdelhaleem, 2005). In this paper, we report the cloning, expression, purification and preliminary X-ray diffraction analysis of the N-terminal region of DDX5 consisting of amino acids 1–305 and spanning domain 1 of the DEAD-box helicase.

2. Experimental procedures

2.1. Cloning, expression and purification

The open reading frame encoding human DDX5 was amplified from a spleen cDNA expression library (Goh *et al.*, 2004). The 5' primer 5'-CGGGATCCATGTCCGGTTATTTCGAGTGACCGAGAC-3' and 3' primer 5'-CCGCTCGAGTTAAAGTGCACCAATGTTATATGAA 3' were used to clone the N-terminal region of DDX5 (residues 1–305) in an expression plasmid with an amino-terminal glutathione *S*-transferase (GST) fusion partner (pGEX6p1, GE Healthcare). The sequence identity was confirmed by DNA sequencing (DNA core facility, IMCB, Singapore).

The fusion protein was expressed in *Escherichia coli* BL21-CodonPlus-RIL (Stratagene). Cultures were first grown overnight at 310 K in Luria–Bertani (LB) medium supplemented with 100 µg ml⁻¹ ampicillin and 20 µg ml⁻¹ chloramphenicol before inoculation into Terrific Broth (TB) supplemented with the same amounts of antibiotics. On reaching an OD₆₀₀ of 0.8, the cultures were cooled to 291 K and induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.2 mM. After an incubation period of 24 h, the cells were harvested at 4000g for 10 min. Bacterial pellets were resuspended in lysis buffer (50 mM Tris–HCl pH 7.4, 300 mM NaCl, 10% glycerol and 2 mM DTT) supplemented with Complete Protease Inhibitor (Roche). For purification, the cells were subjected to sonication. The lysate was cleared by centrifugation (1 h, 15 000g) and the supernatant was mixed with 3 ml glutathione Sepharose resin (GE Healthcare) pre-washed with lysis buffer. Following 3 h of batch binding at 277 K with constant-rotation mixing, four washes with lysis buffer were performed to remove unbound proteins. Removal of the GST tag from the N-terminus of DDX5 (1–305) was achieved by proteolytic cleavage using recombinant 3C protease (GE Healthcare). Approximately 100 µg 3C protease was used per milligram of GST-DDX5 (1–305). Briefly, the resin-bound fusion protein was resuspended in 30 ml lysis buffer containing 3C protease. Cleavage took place overnight at 277 K with constant rotation. The supernatant containing cleaved DDX5 (1–305) was separated by pouring the resin into an empty Econo-Pac column (Bio-Rad). The elutant was concentrated using an Amicon Ultra-15 Centrifugal Filter Device (Millipore) and further purified by size-




Figure 1
SDS–PAGE analysis of the purification stages of DDX5 (1–305). Lane 1, protein molecular-weight standards (kDa); lanes 2–5, fractions collected from the gel-filtration column.

exclusion chromatography through a Superdex S200 column (GE Healthcare) pre-equilibrated with 25 mM Tris–HCl pH 7.4, 300 mM NaCl, 10% glycerol and 2 mM DTT. Peak fractions were analyzed by SDS–PAGE to assess their purity (Fig. 1). The protein concentration was determined by spectrometry using the molar extinction coefficient of DDX5 (1–305) at 280 nm (35 785 M⁻¹ cm⁻¹). The molar extinction coefficient was determined from the protein sequence of DDX5 (1–305) using the *ProtParam* tool (Gasteiger *et al.*, 2005). Pure DDX5 (1–305) was concentrated to 11 mg ml⁻¹. As a consequence of cleavage, five amino acids (GPLGS) remained fused to the N-terminus of DDX5 (1–305).

2.2. Crystallization

DDX5 (1–305) was crystallized *via* the sitting-drop vapour-diffusion method at 288 K using 24-well plates. 1 µl protein solution was mixed with 1 µl reservoir solution and equilibrated against 0.5 ml reservoir solution (Crystal Screens I and II and PEG/Ion Screens I and II; Hampton Research). X-ray diffraction-quality crystals were obtained within two months from drops containing 1 µl protein solution [DDX5 (1–305) at 11 mg ml⁻¹ in 25 mM Tris–HCl pH 7.4, 300 mM NaCl, 10% glycerol and 2 mM DTT] and 1 µl 2% (v/v) Tacsimate pH 4.0, 0.1 M bis-tris pH 6.5 and 20% (w/v) polyethylene glycol (PEG) 3350.

2.3. X-ray diffraction analysis

For cryoprotection, the crystal was soaked in cryosolution [2% (v/v) Tacsimate pH 4.0, 0.1 M bis-tris pH 6.5, 20% (w/v) PEG 3350 and 25% glycerol] and flash-cooled in liquid nitrogen. Native data sets were collected using a Quantum CCD image plate on beamline 13B1 at the National Synchrotron Radiation Research Center (NSRRC), Taiwan. 150 images were collected as 1° oscillations with 1 s exposure. The crystal-to-detector distance was set to 400 mm. The X-ray diffraction pattern of a DDX5 (1–305) crystal is shown in Fig. 2.




Figure 2
Diffraction pattern of DDX5 (1–305) together with resolution rings. The crystal-to-detector distance was 400 mm and the oscillation angle was 1°.



Figure 3
Crystals of DDX5 (1–305). Typically, crystals grew to maximum dimensions of $0.15 \times 0.05 \times 0.05$ mm.

The raw data were integrated and scaled using the *HKL-2000* program suite (Otwinowski & Minor, 1997).

3. Results and discussion

The N-terminal region of DDX5 (1–305) was cloned and expressed in *E. coli* BL21 (DE3). The typical yield of pure DDX5 (1–305) was 2 mg per litre of bacterial culture. Crystals first appeared within two weeks of incubation. Crystals grew to maximum dimensions of $0.15 \times 0.05 \times 0.05$ mm (Fig. 3). Native data were collected from a single crystal of DDX5 (1–305) grown in 2% (*v/v*) Tacsimate pH 4.0, 0.1 M bis-tris pH 6.5 and 20% (*w/v*) PEG 3350 (Fig. 2). The space group was determined to be *I*222, with unit-cell parameters $a = 66.18$, $b = 73.80$, $c = 104.00$ Å, $\alpha = \beta = \gamma = 90^\circ$. The asymmetric unit contained one copy of DDX5 (1–305); the crystal volume per unit molecular weight (V_M) was calculated to be $2.32 \text{ \AA}^3 \text{ Da}^{-1}$, corresponding to a solvent content of 47% (Matthews, 1968). Crystallographic statistics of the native data are summarized in Table 1. Crystallization of full-length DDX5 is actively being pursued, as is a molecular-replacement solution for DDX5 (1–305) using the structure of the conserved domain 1 of DDX3X (Hogbom *et al.*, 2007) as a search model. The percentage sequence identity between the first 305 residues of DDX5 and DDX3X is ~41%.

This work was supported by grants from the Agency for Science, Technology and Research (A*STAR), Singapore. The authors wish

Table 1

Statistics of preliminary data analysis.

Values in parentheses are for the highest resolution shell.

Space group	<i>I</i> 222
Unit-cell parameters (Å, °)	$a = 66.18$, $b = 73.80$, $c = 104.00$, $\alpha = \beta = \gamma = 90$
No. of molecules per ASU	1
Resolution (Å)	25–2.7 (2.8–2.7)
Wavelength (Å)	0.99
Observed reflections	42651 (4013)
Unique reflections	7229 (704)
Redundancy	5.9 (5.7)
Completeness (%)	99.8 (99.9)
R_{merge} (%)	8.5 (48.3)
$\langle I/\sigma(I) \rangle$	19.6 (2.7)

to thank the personnel at NSRRC, Taiwan for their kind help during data collection.

References

- Abdelhaleem, M. (2005). *Clin. Biochem.* **38**, 499–503.
- Benz, J., Trachsel, H. & Baumann, U. (1999). *Structure*, **7**, 671–679.
- Carmel, A. B. & Matthews, B. W. (2004). *RNA*, **10**, 66–74.
- Caruthers, J. M., Johnson, E. R. & McKay, D. B. (2000). *Proc. Natl Acad. Sci. USA*, **97**, 13080–13085.
- Cordin, O., Banroques, J., Tanner, N. K. & Linder, P. (2006). *Gene*, **367**, 17–37.
- Ford, M. J., Anton, I. A. & Lane, D. P. (1988). *Nature (London)*, **332**, 736–738.
- Fuller-Pace, F. V. (2006). *Nucleic Acids Res.* **34**, 4206–4215.
- Fuller-Pace, F. V. & Ali, S. (2008). *Biochem. Soc. Trans.* **36**, 609–612.
- Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D. & Bairoch, A. (2005). *The Proteomics Protocols Handbook*, edited by J. M. Walker, pp. 571–607. Totowa: Humana Press.
- Goh, P. Y., Tan, Y. J., Lim, S. P., Tan, Y. H., Lim, S. G., Fuller-Pace, F. & Hong, W. (2004). *J. Virol.* **78**, 5288–5298.
- Gorbalenya, A. E. & Koonin, E. V. (1993). *Curr. Opin. Struct. Biol.* **3**, 419–429.
- Hogbom, M., Collins, R., van den Berg, S., Jenvert, R. M., Karlberg, T., Kotenyova, T., Flores, A., Karlsson Hedestam, G. B. & Schiavone, L. H. (2007). *J. Mol. Biol.* **372**, 150–159.
- Lane, D. P. & Hoefler, W. K. (1980). *Nature (London)*, **288**, 167–170.
- Linder, P. (2006). *Nucleic Acids Res.* **34**, 4168–4180.
- Linder, P., Lasko, P. F., Ashburner, M., Leroy, P., Nielsen, P. J., Nishi, K., Schnier, J. & Slonimski, P. P. (1989). *Nature (London)*, **337**, 121–122.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Rosler, O. G., Straka, A. & Stahl, H. (2001). *Nucleic Acids Res.* **29**, 2088–2096.
- Sengoku, T., Nureki, O., Nakamura, A., Kobayashi, S. & Yokoyama, S. (2006). *Cell*, **125**, 287–300.
- Shi, H., Cordin, O., Minder, C. M., Linder, P. & Xu, R. M. (2004). *Proc. Natl Acad. Sci. USA*, **101**, 17628–17633.
- Tanner, N. K., Cordin, O., Banroques, J., Doere, M. & Linder, P. (2003). *Mol. Cell*, **11**, 127–138.